• 25 June 2018

    The challenges of using stem cells in neurology

    The development of stem-cell based therapies has been slow even though there are many theoretical applications and benefits associated with these therapies. The challenges of translating potential drugs from clinical...

  • 20 June 2018

    Another BACE inhibitor fails in phase III trials

    On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the...

  • 22 May 2018

    PD-L1 biomarker makes a comeback in bladder cancer

    PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even...

  • 26 April 2018

    Colorectal cancer pipeline insight

    Within the GlobalData Pharma Intelligence Center, there are profiles of many drug candidates that focus on the prevention and treatment of colorectal cancer.

Go Top